Antibodies to a synthetic peptide corresponding to the 141 to 160 amino acid sequence of the protein VPI of type O foot-and-mouth disease virus (FMDV) neutralize a wider range of type O isolates than anti-virion serum. Extending this peptide at the amino terminus reduced the number of strains neutralized by the antipeptide sera. Reactions with antisera to peptides representing non-contiguous native sequences showed that it was also possible to increase the number of strains effectively neutralized. Selected substitutions of a single amino acid at position 148 markedly altered the neutralizing specificity of antibodies elicited by the 141 to 160 peptide. In particular, a peptide with an L ~ S substitution at this position induced antibodies which neutralized a type O and a type A virus equally, and guinea-pigs inoculated with it were protected from challenge with either virus. Attempts to isolate variant viruses resistant to neutralization with anti-peptide antibody indicated that these occurred at low frequency, and there was some evidence that resistance may be partially conferred by mutations outside the peptide sequence.
INTRODUCTION
Foot-and-mouth disease is the most economically important affliction of domestic livestock. One of the greatest problems in its control with conventional vaccines prepared from inactivated virus particles is the occurrence of the virus as seven distinct serotypes within Milch there is considerable antigenic variation. By definition, there is no demonstrable crossprotection between these serotypes, so that an animal which has recovered from infection with a virus of one serotype is as susceptible to infection with virus of another serotype as an animal which has not previously been infected. Moreover, antigenic variation within a serotype can affect the success of vaccination programmes.
In vitro neutralization tests have been extremely valuable for assessing the potency and applicability of vaccines. From a large number of observations made in several laboratories over many years on assessments of vaccine potency, it is generally accepted that, depending on the virus strain, 50 ~o of cattle with minimum serum neutralizing titres of log~ 0 1-0 to 1.8 against 100 tissue culture infectious doses of virus are protected against the intradermal inoculation of 10 000 IDs0 of the homologous virus into the tongue. By determining the ratio (r) of the neutralizing titres of sera from vaccinated animals against virus from a field outbreak and the vaccine strain it is possible to estimate the antigenic relationship between the two viruses and the likely efficacy of the vaccine in controlling the outbreak (Rweyemamu & Hingley, 1984) .
The availability of amino acid sequences of the capsid proteins from foot-and-mouth disease virus (FMDV) and the ability to synthesize peptides corresponding to these sequences have made it possible to study the biochemical basis of antigenic variation. In particular, the identification of the 138 to 154 region of VP 1 as a major immunogenic determinant (Strohmaier et al., 1982) , and the demonstration that synthetic peptides spanning this region induce neutralizing, protective antibody (Bittle et al., 1982; Pfaffet al., 1982) , have allowed a detailed examination to be made of antigenic variation. The 141 to 160 tract contains a highly conserved RGD (145-147) sequence which contributes to several neutralizing antibody binding sites (Parry et al., 1985 Thomas et al., 1988; Pfaffet al., 1988; Bolwell et al., 1989) , and also plays a prominent role in the attachment of virus to susceptible cells . Earlier studies with four variants of a serotype A, subtype 12, FMDV strain had shown that the amino acids at the first position (148) after the RGD sequence and at position 153 were crucial in determining the specificity of both anti-virus and anti-peptide sera (Rowlands et al., 1983) . Subsequently, Ouldridge et al. (1986a,b) demonstrated that the residue at 148 was also important in determining whether heterologous strains of FMDV were neutralized by antisera to a peptide corresponding to the 141 to 160 sequence of two viruses belonging to the O1 subtype, namely O1 BFS and O1 Kaufbeuren. The specific involvement of the amino acid at position 148 in native neutralizing epitopes of type O FMDV particles has been reported by Xie et al. (1987) and Pfaff et al. (1988) . The present paper describes the effects of selected substitutions at position 148 in peptides otherwise corresponding to the type O1 141-160 sequence, and of varying the length of the natural peptide sequence, on the neutralizing specificity of their antisera. The results show that it is possible to increase both the homo-and heterotypic immunogenic spectra of potential synthetic vaccines.
METHODS
Viruses. The O1 BFS 1860 and C3 Indaial viruses used in this study are FMDV vaccine strains from Coopers Animal Health Ltd. The low and high passage O 1 Kaufbeuren strains are the seventh and 64th passage isolates described by Strohmaier et al. (1982) . The B and C variants of A 1 z 119 virus are those identified by Rowlands et al. (1983) . O Colombia 9834 virus was obtained from the VECOL Laboratories, Colombia. The remaining type O viruses are primary field isolates obtained from the FMDV World Reference Laboratory, Institute for Animal Health, Pirbright, U.K. and subsequently passaged three times in baby hamster kidney (BHK)21 cells. One of these viruses, O Thailand 1/80, was found to be a mixed antigenic population and two plaque-picked clones (clones 2 and 10), respectively susceptible and resistant to neutralization by O~ BFS 1860 antisera, were isolated (Ouldridge et al., 1986b) . All virus stocks were passaged in BHK21 cells in the preseffce of Eagle's medium, supplemented with 10 ~ tryptose phosphate broth, and stored at -20 °C in an equal volume of glycerol as clarified tissue culture harvests.
Peptides. These were synthesized to derived VP1 sequences of O1 Kaufbeuren (Kurz et al., 1981) , with 'unnatural' cysteine residues at their carboxy termini, using Merrifield solid-phase tBoc chemistry and the 'tea bag' method of Houghten (1985) . Four peptides corresponding to the 141 to 160 sequence were synthesized with selected substitutions of R, T, S and I at position L148. Two peptides of non-contiguous sequences of O1 Kaufbeuren, , were also produced.
Antibody preparations. Antisera were raised in Dunkin-Hartley guinea-pigs. Anti-virus serum was obtained by two inoculations 28 days apart of 20 pg of acetylethyleneimine-inactivated virus particles purified by the method of Brown & Cartright (1963) . For studying the effect of substitutions at position 148, antisera were raised to two inoculations of 500 Ixg of peptide 35 days apart and blood was collected 28 days after the second inoculation. Antipeptide antisera for other studies were produced by a similar regime, but the amounts used were smaller (100 to 200 lag per guinea-pig). All antigens were emulsified with an equal volume of incomplete Freund's adjuvant just before intramuscular injection. Antisera to each antigen were collected from five guinea-pigs and pools of an equal volume were used for specificity testing. Antisera raised against a fusion protein consisting of four copies of the 137--162 sequence linked to a/J-galactosidase molecule (Broekhuijsen et al., 1987) and a neutralizing murine monoclonal antibody (MAb) to this protein, produced at the TNO Laboratory, Rijswijk, The Netherlands, were also used.
Neutralization assay. This was performed as a two-dimensional (2D) micro-c.p.e, test using BHK21 cells as the indicator of residual virus infectivity as described by Rweyemamu et al. (1978) . Antibody titres are expressed as log10 of the reciprocal serum dilution giving 50 ~ neutralization of 100 tissue culture infective doses of virus (log lo SNso/100 TCID50). The antigenic relationship of viruses based on their neutralization by each serum is given by the ratio: r = neutralization titre against the heterologous virus/neutralization titre against the homologous virus. The significance of differences in the values of r obtained were evaluated according to the criteria of Rweyemamu & Hingley (1984) .
Enzyme-linked immunosorbent assays (ELISA)
.Flexible PVC microplates were coated at 4 °C overnight with peptides diluted in carbonate buffer (15 mM-NazCO 3, 35 mM-NaHCO3) at equimolar concentrations equivalent to 4 Mg/ml of peptide 141-160C. After washing with Dulbecco's phosphate-buffered saline containing 0.05~ Tween 20, 50 ttl of serial doubling dilutions of antibody in wash buffer plus 1 ~ bovine serum albumin were added to each well and the plates incubated at 37 °C for 1 h. After rewashing, 50 ~tl ofperoxidase-labelled anti-mouse IgG (Miles Laboratories), diluted 1 : 2000, were added to each well and the plates were reincubated. Following a final wash 50 ~tl peroxide-o-phenylene diamine substrate in citrate buffer was added to each well. The colour development was stopped with 12-5~ sulphuric acid, and absorbances were read at 492 nm using a Titertek Multiskan spectrophotometer.
Virus sequencing. BHK21 cells, infected with virus at a multiplicity of 100 p.f.u./cell, were harvested 3 h postinfection and the viral RNA was extracted and purified as described previously (Rowlands et al., 1978) . The RNA was used directly as a template for primer extension sequencing reactions (Clarke et at., 1987a) , utilizing a single primer complementary to the 3' side of the main immunogenic loop of VPI.
RESULTS

Effects of peptide length on antiserum specificity
Initially the serological relationships of 12 type O FMDV strains were assessed by 2D microneutralization assays using guinea-pig antisera against virus particles and peptides 141-160C and t 35-160C. The strains were selected on the basis of previous studies which had shown the majority of them to be antigenically divergent from the O1 BFS and O1 Kaufbeuren vaccine viruses when titrated against anti-virion sera. The results obtained from duplicate or triplicate assays confirmed these earlier observations, eight of the strains having r values significantly less than one when compared with virus antiserum (Table 1) . However, six out of the eight strains (low passage O1 Kaufbeuren, O Austria 1/81, O Indonesia 7/83, O Colombia 9834, O Malaysia 2/83 and O Saudi Arabia 28/83) were neutralized as efficiently as the homologous viruses by one or both of the peptide antisera, showing these sera were less specific than anti-virus serum. This reduced specificity was also evident for bovine antiserum against peptide 135-160C which, in a limited comparison, had a similar specificity to the equivalent guinea-pig antiserum (Table 1) . Guinea-pig antiserum to the longer 135-160C peptide appeared more specific than peptide 141- * Denotes values of r significantly less than 1.0 (P = 0.05).
? Denotes values of r significantly less than 1.0 (P = 0.01). ND, not determined. of r significantly less than 1.0 (P = 0.05). of r significantly less than 1.0 (P = 0.01).
0.07:~ <0.01~
160C antiserum in that it did not neutralize the low passage O1 Kaufbeuren and O Hong Kong 21/70 strains to the same extent. The effect of the length of the peptide immunogen on the specificity of antibodies induced was investigated. Seven of the FMDV strains used in the first study were further assayed against antisera to a compound peptide corresponding to the carboxy terminus of VP1 linked to the amino terminus of the major immunogenic region with spacing amino acids between them (CC-200-213-PPS-141-158 PCG; di Marchi et al., 1986) , and to a peptide representing a double copy of residues 145 to 150 linked to a single copy of the 151-160 region (145-150 to 145-160C). Polyclonal antiserum and a MAb to a fusion protein composed of four copies of the 137-162 tract attached to a single fl-galactosidase molecule [(137-162) ,-flgal], described by Broekhuijsen et al. (1987) were also evaluated. The mean titres of these antisera, from triplicate assays, against the seven viruses are shown in Table 2 (a), and the derived relationship (r) between the viruses determined by each serum is shown in Table 2 (b). The monoclonal and polyclonal antibody preparations to the fusion protein had highly similar specificities. Both showed increased specificity compared to peptide 141-160C antiserum in that they had diminished ability to neutralize O Hong Kong 21/70 virus, but were less specific than peptide 135-160C antiserum since they neutralized the low passage O1 Kaufbeuren strain well. Antisera to the two noncontiguous peptides, on the other hand, had the broadest coverage, efficiently neutralizing all the strains tested, including 06 V1, except O Thailand 1/80 clone 10. 
Epitope mapping of the fusion protein MAb
The antibody was titrated in an indirect ELISA against the homologous fl-galactosidase fusion protein, containing four copies of the FMDV 137-162 region, and a similar fusion protein containing a single copy, using protein concentrations that contained an equal number of copies of the FMDV-specific sequence. Serial dilutions of the antibody produced virtually identical reaction curves with both proteins (data not shown). This suggested that the binding site was a continuous linear epitope and not a discontinuous product of secondary structure induced by multiple sequences. The antibody was also titrated against equimolar concentrations of a nested set of peptides, serially reduced by one amino acid at the amino terminus from residues 137-160C to 148-160C. The antibody reacted equally well with peptides 137-160C to 140-160C, showed reduced reactivity with the peptide 141-160C which was further reduced with peptide 142-160C, and did not recognize peptides 143-160C to 148-160C (Fig. 1) . These results imply that V 141 and P 142 contribute, non-critically, to the MAb binding site, and that N 143 is crucially involved.
Effect of amino acid 148 on the specificity of peptide antisera
Pooled antisera to five individual peptides differing only in the amino acid at position 148, and an antiserum to an equimolar mixture of three of these peptides totalling 500 gg per dose, were compared for neutralizing specificity. Their activity was assessed against two O1 strains (BFS and Kaufbeuren) that showed complete homology of the 141 to 160 sequence, three type O viruses readily distinguishable by polyclonal anti-virus serum (06 V 1, O Thailand 1/80 clone 10 and O Philippines), two variants (B and C) of A~ 2 119 virus and C3 Indaial. The relevant VP1 sequences of these viruses are shown in Fig. 2 . The mean serum titres from triplicate independent experiments are shown in Table 3 
Fig. 2. Aligned sequences, using the single-letter amino acid code, of the VP 1 135-160 region of FMDV strains included in the specificity studies, showing differences from the O1 Kaufbeuren sequence.
• Denotes amino acid deletions, t Denotes undetermined amino acids.
peptide containing the Lo S substitution, had similar neutralizing titres against On Kaufbeuren and O1 BFS. As expected, antiserum to the native sequence peptide neutralized the selected heterologous O strains no better than anti-virus serum, but showed some neutralization of the C3 virus, which also has a leucine residue at position 148. There was, however, no detectable recognition in these assays of the B variant of A12 119 virus which also has leucine at 148. The specificity of antisera to peptides containing substitutions at position 148 with amino acids occurring at the same position in other O viruses was not as anticipated. Antisera to peptides with LoT and LoI changes, which occur in the 06 V1 and O Philippines strains respectively, continued to give the highest titres against the O1 BFS and Ox Kaufbeuren viruses, but there was no improved relative neutralization of the strains possessing the specific amino acid at position 148. Surprisingly, however, these anti-peptide antisera showed some neutralization of A x 2 119C virus. Antiserum to the Lo R also peptide did not neutralize the O virus with the homologous amino acid at 148 (O Thailand 1/80 clone 10) any more efficiently than antiserum to the native O1 Kaufbeuren peptide, but showed much improved neutralization of 06 VI (148 T) and some activity against A12 119B (148 L). This result was confirmed by testing the five individual sera forming the antiserum pool to the Lo R peptide which, although varying in titre, all produced the same profile of reactions with the eight strains (data not shown). The most significant result was the finding that antiserum to the peptide with the A~2 119C-specific substitution of LoS, although of low titre, neutralized O1 BFS, O1 Kaufbeuren and A~ 2 119C equally. This was corroborated by titrating the serum in the more sensitive mouse index test (Skinner, 1953) , in which the infectivity titres ofOt BFS and A~ 2 119C were reduced by 3.5 and 3.9 loglo respectively compared to 5.2 and <0-2 log~0 for the native anti-peptide antiserum.
Cross-protection of guinea-pigs with a single peptide
The relationship of the observed heterotypic cross-neutralization to immunity was assessed in a guinea-pig protection test. Eight animals were inoculated twice with the LoS peptide as described, except that the first inoculum was emulsified with complete Freund's adjuvant, and test bled 27 days after the second injection. At 28 days after the boost three animals were challenged with I000 guinea-pig infectious doses ofO1 BFS and four with the same dose of A~2 l" denotes r values significantly less than 1.0 (P = 0.05). 119C, one animal having died of unknown causes during the response period. Four unimmunized guinea-pigs were also challenged with each virus. All eight of the non-immune animals developed lesions, whereas only one guinea-pig, that with the lowest serum titre, from each of the immunized groups developed lesions (Table 4) .
N. R. PARRY AND OTHERS
Anti-peptide antibody-resistant variant viruses
Several attempts were made to isolate mutants, resistant to neutralization with anti-peptide 141-160C antiserum, from the triple plaque-purified clone (Octl) of the O1 BFS 1860 vaccine strain described by Barnett et al. (1989) . The virus was either preincubated with equal volumes of undiluted pooled sera from cattle, rabbits of guinea-pigs before plating out on BHK monolayers under agar overlay containing a 1:20 dilution of the same antibody, or passaged three times in the presence of high concentrations of antiserum before plating out as described. All samples produced a uniform population of plaques that were considerably smaller than those on control plates with no antibody in the overlay. Progeny virus from individual plaques picked at random were all fully neutralized by the selecting antiserum.
Subsequently virus was passaged in the presence ofpeptide 141 160C antiserum from a single guinea-pig that had a particularly high neutralizing titre. After three passages the virus was plaque-assayed as above, but no evidence of a resistant subpopulation was observed. It was passaged a further three times under antibody pressure with the addition of a 1 : 20 dilution of anti-guinea-pig IgG (Miles Laboratories). The progeny was again assayed in the presence of selecting antibody, and only four plaques larger than the rest were evident, These were picked and the viruses grown from them were characterized. Two were neutralized as efficiently as the parent by the selecting antiserum and the other two were fully resistant (r = 0.01). The frequency of resistant mutants occurring at the sixth passage was ! 0-7"~. Surprisingly, the resistant variants were still fully neutralized by 141-160C antisera from four other guinea-pigs from the same group as the animal providing the selecting antiserum, and they were only partially resistant (r = 0.3) to peptide 135-160C antisera raised in cattle. Sequence analysis showed that the two mutants had an N--,S substitution at position 143 with no other changes within the 127 to 166 region of VP1, while the two neutralizable clones had the parental sequence.
DISCUSSION
The first understanding of the biochemical basis of antigenic variation of FMDV was provided by Rowlands et al. (1983) in a study of four mutants of A1: 119 virus. They showed that amino acid substitutions at either position 148 or 153 in the VP 1 of one or other of these variants resulted in resistance to neutralization by antisera to both virus particles and peptide 141-160C of the heterologous variants. Subsequently, Ouldridge et al. (1986 b) reported that antiserum to a peptide corresponding to the 141-160C VP1 sequence of O1Kaufbeuren virus neutralized a range of type O FMDV strains that differed considerably in their 141 to 160 sequences. Since most of these differences were located within residues 141 to 144 with some also in the 152 to 160 region, cross-neutralization appeared to be associated with homology within the 145 to 151 tract. In particular, the ability of both anti-peptide 141-160C antiserum and O1 BFS 1860 anti-virion serum to neutralize clone 2 of O Thailand 1/80 virus, which has a homologous leucine residue at position 148, but not clone 10, which has an L~R substitution, again indicated the importance of the amino acid at position 148 in determining antibody specificity. The data presented here show that single amino acid substitutions at position 148, in peptides otherwise corresponding to the native 141 to 160 sequence of O1 BFS 1860 and O1 Kaufbeuren viruses, markedly affected the specificity of the antibody induced. In general, the effects of these substitutions were not predictable as demonstrated by the neutralization of the 06 V1 and A12 119C virus strains by antisera to peptides which did not contain the homologous substitutions. When a substitution specific for the A12 119C virus was introduced into the O1 141 to 160 sequence, however, the induced antibody neutralized the O1 BFS 1860 and A12 119C viruses equally, and the antibody was protective. These observations are consistent with the evidence that the conserved RGD (145 to 147) sequence is a major component of the cell attachment site of FMDV A. Y. Surovoy, personal communication) and thus contributes to the epitopes recognized by some neutralizing MAbs, the specific binding of which is modulated by the flanking sequences .
The O1 viruses (BFS, Kaufbeuren, Lausanne), isolated from the major European outbreak of FMD that occurred between 1966 and 1968, are extensively used to formulate effective vaccines that have world-wide application. Even so, Ouldridge et al. (1986a, b) reported that peptide 141-160C elicited antibody which neutralized a wider range of type O strains than antisera to these viruses. Our findings confirm and extend that study and show, moreover, that the additional virus strains neutralized have a wide geographical distribution (Europe, South East Asia, South America and the Middle East) and are, therefore, not likely to represent viruses from related outbreaks. Furthermore, this peptide antiserum neutralized a heterotypic C3 virus which, in common with the O1 virus group, has a leucine residue at position 148. Although not evident from the microneutralization test data presented here, other experiments using the more sensitive mouse index neutralization test have shown that peptide antisera are also capable of neutralizing the A12 119B (L 148) and Asia 1 Pakistan (R 148) viruses (F. Brown, unpublished data) . The majority of these results were obtained with the antisera from laboratory animals; however, antipeptide sera raised in cattle also show increased neutralization of viruses not well neutralized by virus antiserum (Table 1 ). In addition, guinea-pig sera from vaccinated animals have previously been shown to have strain specificities very similar to vaccinated cattle sera .
The major design objective for peptide vaccines is maximum immunogenicity allied to broad cross-reactivity. Peptides extended by natural contiguous sequences at the amino terminus beyond amino acid 141 have increased immunogenicity (Francis et al., 1987a) , but our comparison of antisera to peptides 141-160C and 135-160C indicated that the specificity increased too, although it remained broader than for anti-virion sera. Leban et al. (1986) have also noted that shorter FMDV peptides evoke a more cross-reactive antibody response. Although it is possible that these longer peptides include more epitopic residues, our absorption studies of peptide antisera with virus particles have indicated that the extended peptides provide improved presentation of the 141 to 150 region to the immune system (Parry et al., 1988) . This region has been reported to contain major components of both broadly cross-reactive and more specific discontinuous neutralizing epitopes Parry et al., 1989) , and the possibility arises that the increased immunogenicity may be due to better exposure of the more specific epitopic regions. The antibody preparations to the (137-162)4-/~-galactosidase construct allowed this hypothesis to be tested. The fusion protein is highly immunogenic (Broekhuijsen et al., 1987) and its polyclonal antiserum and MAb had very similar specificities, which were intermediate between those of the 135-160C and 141-160C peptide antisera. ELISA titrations indicated that the MAb bound to a linear epitope which was located around amino acids 140 to 143. This finding agrees with studies of anti-virion MAbs which mapped components of the more specific antibody epitopes on the amino-terminal side of residue 145 and the cross-reactive epitopes on the carboxy-terminal side of this residue . Similarity of specificity implies that the MAb is representative of the polyclonal response and suggests, therefore, that longer peptides do favour the presentation of less cross-reactive immunogenic regions of the 140 to 150 sequence.
The two peptides which induced the most cross-reactive neutralizing responses were those synthesized to non-contiguous native sequences. A peptide corresponding to the 145-160C sequence alone only induced love titre neutralizing antibody (Francis et al., 1987a) , which was not suitable for extensive specificity studies although it neutralized A12 119B virus (L 148) as well as the homologous O viruses (N. R. Parry & F. Brown, unpublished data) . The 145 to 150 region constitutes a major component of an epitope recognized by a MAb which neutralizes a range of type O strains, including 06 V1, that are not readily neutralized by polyclonal antivirion serum . The 145-150-145-160C peptide was synthesized, therefore, with the intention of increasing immunogenicity while retaining broad specificity. This was successful; antiserum of reasonable titre was obtained (Table 2 a) which neutralized three out of four type O isolates, including 06 V1, that were not efficiently neutralized by virus antiserum (Table 2 b ). The peptide corresponding to the C terminus of VP1 coupled to the amino terminus of the 141 to 158 sequence has been shown to protect cattle from virus challenge and is more immunogenic than the 141 to 158 region alone (di Marchi et al., 1986) , although little or none of the increased response appears to be directed at the 200 to 213 region itself (Doel et al., 1988) . There is serological evidence that the two regions comprising this peptide are components of a single antigenic domain on the virus particle which contains both cross-reactive and specific epitopes (Parry eta!., 1985 (Parry eta!., , 1989 , and the recently resolved atomic structure of the virus shows that the two components are provided by adjacent VP1 molecules (Acharya et al., 1989) . Presumably the compound peptide favours a highly immunogenic configuration of this region in which the more cross-reactive portions remain immunodominant.
In addition to the 141 to 160 and 200 to 213 regions of VP 1, the 160 to 180 tract and portions of VP2 and VP3 have also been shown to be involved in the binding of neutralizing MAbs (Robertson et al., 1984; Pfaff et al., 1988 ; Thomas et al., 1988; Parry et al., 1989) . This raises the question of whether the use of peptides, representing only a small part of VP 1, as vaccines could lead to the rapid appearance of neutralization-resistant variant viruses, notwithstanding their broad cross-reactivity. Our attempts to isolate such mutants indicate that this is not the case. Escape mutants were isolated only under pressure from high titre antiserum from a single animal, but these continued to be fully neutralized by sera from other animals both from the same immunization group and from other groups immunized with the same peptide at different times. This suggests that this particular animal exhibited a more restricted response than is normal. Moreover, the resistant mutants only occurred at a frequency of 10 -v'4 after six passages under antibody pressure, three of which were enhanced with anti-species IgG, compared to their regular isolation at a frequency of approximately 10 -4 using MAbs. This strongly suggests that two amino acid substitutions were required to confer resistance to peptide antiserum. Only one substitution was found within the sequence spanned by the peptide, however, and implies that a second substitution that affected its conformation had occurred in a region linearly, though not necessarily spatially, distant from it. Rowlands et al. (1983) also found that two amino acid substitutions were required to alter substantially the neutralization of variants of type A FMDV with anti-peptide sera, although these both occurred within the peptide sequence itself. However, evidence for the substitution of an amino acid, not directly involved in antibody binding, apparently conferring on type O FMDV resistance to neutralization with a MAb by altered conformation of the 141 to 160 region has been reported previously . Furthermore, the high and low passage strains of O1 Kaufbeuren could be distinguished antigenically with peptide 135-160C antiserum despite complete sequence homology between them in this region (Table 1, Fig. 2 ), which implies probable conformational differences caused by substitutions elsewhere.
It is clear from these findings that relatively minor manipulations of native sequences or single amino acid substitutions can result in increases in both the homo-and heterotypic crossreactivity of antisera raised against FMDV peptides. It is currently not possible to predict the effects of such changes, but the application of nuclear magnetic resonance and circular dichroism techniques to study the conformation of peptides in solution may eventually provide this facility (P. Mascagni, personal communication). The cross-reactivity of even the most specific peptide antiserum tested was greater than that of anti-virus antiserum. This fact, together with the difficulties experienced in obtaining virus mutants under anti-peptide antibody pressure, makes it unnecessary to postulate that a 'cocktail' of a large number of peptide sequences would be required to formulate an efficacious vaccine for wide field application. The major problem remaining in the development of peptide vaccines against FMDV is that none so far reproducibly elicits a high-titre antibody response in cattle. The use of multiple copies of epitopes enhances immunogenicity (Broekhuijsen et al., 1987) , and expressing the peptide as a fusion protein on the surface of hepatitis B core antigen particles enhances it by many orders of magnitude (Clarke et al., 1987b) , although the latter preparation has yet to be evaluated in cattle. From studies of the responses to FMDV peptides in different strains of mice, Francis et al. (1987b) demonstrated that restriction of these responses occurred at the T cell level, and this could be overcome with peptides which incorporated both the specific B cell epitope and 'foreign' T helper cell epitope sequences. It is conceivable, therefore, that the identification of appropriate cattle T cell epitopes which can be mimicked by short linear sequences may be one of the last important steps in the provision of a successful synthetic vaccine.
